Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia

Purpose To evaluate the effect of intravitreal bevacizumab injection for treating type 1 idiopathic macular telangiectasia (IMT). Methods Retrospective case series of five eyes of five male patients with type 1 IMT that were treated with 2–3 injections of intravitreal bevacizumab. Best-corrected vis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Eye (London) 2010-09, Vol.24 (9), p.1492-1497
Hauptverfasser: Takayama, K, Ooto, S, Tamura, H, Yamashiro, K, Otani, A, Tsujikawa, A, Yoshimura, N
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose To evaluate the effect of intravitreal bevacizumab injection for treating type 1 idiopathic macular telangiectasia (IMT). Methods Retrospective case series of five eyes of five male patients with type 1 IMT that were treated with 2–3 injections of intravitreal bevacizumab. Best-corrected visual acuity, foveal thickness obtained by optical coherence tomography, and fluorescein angiography (FA) were monitored over a period of up to 12 months. Results The average follow-up period was 17.0 months (range, 12–21 months). The mean logarithm of the minimal angle of resolution visual acuity was 0.295 at baseline and 0.254 ( P =0.194) and 0.311 ( P =0.461) at 3 and 12 months, respectively, after the initial injection. At 12 months, visual acuity had improved in one eye, remained stable in three eyes, and decreased in one eye. The mean foveal thickness was 479  μ m at baseline; at 1 month after the therapy, marked reduction of macular oedema was seen only in one eye. The mean foveal thickness was 418  μ m ( P =0.287) and 473  μ m ( P =0.482) at 3 and 12 months after the initial injection, respectively. At 12 months, the foveal thickness had decreased by >100  μ m in one eye, but had increased by >100  μ m in two eyes. FA did not show a reduction in late leakage. Conclusions Treatment with intravitreal bevacizumab does not appear to improve visual acuity or retinal oedema in type 1 IMT.
ISSN:0950-222X
1476-5454
DOI:10.1038/eye.2010.61